Analysts at Jefferies Didn’t Change their Hold rating for Helmerich & Payne (HP) with $69.0 Price Objective; ELEKTA B SHARES (EKTAF) Shorts Decreased By 21.68%

Among 36 analysts covering Helmerich & Payne (NYSE:HP), 9 have Buy rating, 8 Sell and 19 Hold. Therefore 25% are positive. Helmerich & Payne has $94 highest and $14 lowest target. $58.70’s average target is -20.34% below currents $73.69 stock price. Helmerich & Payne had 121 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was downgraded by Bank of America to “Neutral” on Thursday, December 8. The stock has “Equal-Weight” rating by Stephens on Monday, March 7. The stock of Helmerich & Payne, Inc. (NYSE:HP) earned “Sector Perform” rating by RBC Capital Markets on Friday, December 16. The rating was maintained by Jefferies with “Hold” on Thursday, August 31. On Monday, November 30 the stock rating was upgraded by Guggenheim to “Buy”. The rating was maintained by Piper Jaffray with “Hold” on Thursday, September 7. The company was maintained on Wednesday, October 11 by BMO Capital Markets. Iberia Capital Partners downgraded Helmerich & Payne, Inc. (NYSE:HP) on Monday, September 21 to “Sector Perform” rating. RBC Capital Markets maintained Helmerich & Payne, Inc. (NYSE:HP) rating on Thursday, December 21. RBC Capital Markets has “Hold” rating and $68.0 target. RBC Capital Markets maintained the stock with “Hold” rating in Friday, September 1 report.

ELEKTA B SHARES (OTCMKTS:EKTAF) had a decrease of 21.68% in short interest. EKTAF’s SI was 16.57 million shares in January as released by FINRA. Its down 21.68% from 21.16M shares previously. With 80,600 avg volume, 206 days are for ELEKTA B SHARES (OTCMKTS:EKTAF)’s short sellers to cover EKTAF’s short positions. It closed at $9.24 lastly. It is down 0.00% since January 26, 2017 and is . It has underperformed by 16.70% the S&P500.

Elekta AB develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company has market cap of $3.50 billion. The firm offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. It has a 74.52 P/E ratio. The Company’s neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform.

Since December 15, 2017, it had 0 insider purchases, and 1 sale for $147,679 activity. $147,679 worth of Helmerich & Payne, Inc. (NYSE:HP) shares were sold by MARSHALL CHAPMAN PAULA.

Investors sentiment increased to 0.96 in Q3 2017. Its up 0.03, from 0.93 in 2017Q2. It is positive, as 37 investors sold Helmerich & Payne, Inc. shares while 154 reduced holdings. 50 funds opened positions while 133 raised stakes. 112.20 million shares or 3.56% less from 116.34 million shares in 2017Q2 were reported. Shell Asset reported 0.03% in Helmerich & Payne, Inc. (NYSE:HP). Raymond James Assocs has invested 0.01% in Helmerich & Payne, Inc. (NYSE:HP). Tci Wealth Advisors stated it has 56 shares or 0% of all its holdings. Steadfast Capital Management Limited Partnership has invested 0.17% in Helmerich & Payne, Inc. (NYSE:HP). Wellington Management Group Incorporated Ltd Liability Partnership accumulated 0% or 393,439 shares. Dnb Asset Management As, a Norway-based fund reported 10,445 shares. Assetmark Inc holds 0% or 906 shares in its portfolio. Peak6 Lp has 9,747 shares. Reilly Financial Advsrs Ltd Liability accumulated 400 shares or 0% of the stock. Fruth Inv owns 16,100 shares or 0.38% of their US portfolio. Private Advisor reported 0.01% stake. Cap Investment Counsel has invested 0.92% in Helmerich & Payne, Inc. (NYSE:HP). Northpointe Capital Limited Liability Company reported 44,719 shares. Dekabank Deutsche Girozentrale reported 21,765 shares. State Street accumulated 6.44M shares.

The stock increased 3.24% or $2.31 during the last trading session, reaching $73.69. About 3.51M shares traded or 109.07% up from the average. Helmerich & Payne, Inc. (NYSE:HP) has risen 4.51% since January 26, 2017 and is uptrending. It has underperformed by 12.19% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: